Quest Diagnostics (DGX) Stock Price, News & Analysis

Company Overview

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. Quest also offers specialized esoteric testing, employer and occupational health testing, clinical trial laboratory services and health information solutions designed to integrate lab data into provider and population health workflows. These capabilities are delivered through laboratory infrastructure, patient collection sites and digital tools that enable ordering, reporting and analytics.

Quest primarily serves the United States healthcare market—providing testing and related services to physician practices, hospitals, payers, employers and governmental agencies—while maintaining capabilities that support international clinical trials and diagnostics initiatives. The company has operated for multiple decades and is structured with centralized laboratory operations, regional service locations and an executive leadership team responsible for strategic, clinical and operational oversight.

Key Stats

• Today's Range: $187.90 to $190.99
• 50-Day Range: $189.04 to $211.75
• 52-Week Range: $164.65 to $213.50
• Volume: 739,938 shs
• Average Volume: 1.08 million shs
• Market Capitalization: $21.13 billion
• P/E Ratio: 21.09
• Dividend Yield: 1.80%
• Price Target: $216.58
• Consensus Rating: Moderate Buy

Quest Diagnostics Stock Analysis - MarketRank™

Quest Diagnostics scored higher than 98% of companies evaluated by MarketBeat, and ranked 13th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and no sell ratings.

Upside Potential

Quest Diagnostics has a consensus price target of $216.58, representing about 13.5% upside from its current price of $190.84.

Amount of Analyst Coverage

Quest Diagnostics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.66%

Earnings Growth

Earnings for Quest Diagnostics are expected to grow by 7.66% in the coming year, from $10.71 to $11.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quest Diagnostics is 21.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quest Diagnostics is 21.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.45.

Price to Earnings Growth Ratio

Quest Diagnostics has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Quest Diagnostics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.49% of the float of Quest Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Quest Diagnostics has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Quest Diagnostics has recently decreased by 14.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Quest Diagnostics pays a meaningful dividend of 1.82%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Quest Diagnostics has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Quest Diagnostics is 38.01%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 29.84% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.7 / 5
• News Sentiment: 1.51

News Sentiment

Quest Diagnostics has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.

Search Interest

16 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

2 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,945,262.00 in company stock.

Percentage Held by Insiders

0.88% of the stock of Quest Diagnostics is held by insiders.

Percentage Held by Institutions

88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DGX Stock Analysis - Frequently Asked Questions

How have DGX shares performed this year?

Quest Diagnostics' stock was trading at $173.47 at the beginning of 2026. Since then, DGX stock has increased by 10.0% and is now trading at $190.84.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) issued its quarterly earnings data on Tuesday, April, 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.37 by $0.13. Quest Diagnostics's revenue was up 9.2% on a year-over-year basis.
Read the conference call transcript.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics' board authorized a stock buyback program on Tuesday, February 10th 2026, which authorizes the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 4.7% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's management believes its shares are undervalued.

Does Quest Diagnostics have any subsidiaries?

Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more.

When did Quest Diagnostics IPO?

Quest Diagnostics (DGX) raised $12 million in an initial public offering on Tuesday, January 7th 2025. The company issued 2,300,000 shares at a price of $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO.

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' top institutional investors include Dimensional Fund Advisors LP (1.76%), Bank of New York Mellon Corp (0.59%), Principal Financial Group Inc. (0.48%) and Swiss National Bank (0.29%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney.
View institutional ownership trends.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Record date for 4/20 Dividend: 4/06/2026
• Ex-Dividend for 4/20 Dividend: 4/06/2026
• Dividend Payable: 4/20/2026
• Last Earnings: 4/21/2026
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:DGX
• CIK: 1022079
• Web: www.questdiagnostics.com
• Phone: (973) 520-2700
• Fax: 201-462-4169
• Employees: 57,000
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Quest Diagnostics: $216.58
• High Price Target: $235.00
• Low Price Target: $178.00
• Potential Upside/Downside: +13.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.05
• Trailing P/E Ratio: 21.09
• Forward P/E Ratio: 17.82
• P/E Growth: 2.25
• Net Income: $992 million
• Net Margins: 9.07%
• Pretax Margin: 12.20%
• Return on Equity: 15.60%
• Return on Assets: 7.06%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.18
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $11.04 billion
• Price / Sales: 1.91
• Cash Flow: $15.32 per share
• Price / Cash Flow: 12.46
• Book Value: $69.25 per share
• Price / Book: 2.76

Miscellaneous

• Outstanding Shares: 110,700,000
• Free Float: 109,722,000
• Market Cap: $21.13 billion
• Optionable: Optionable
• Beta: 0.60